Literature DB >> 33768860

Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial.

Matteo Trimarchi1,2, Pietro Indelicato1,2, Alessandro Vinciguerra1,2, Mario Bussi1,2.   

Abstract

Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well-tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid-dependent disease, and high rates of recurrence of nasal polyps after surgery.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DUPIXENT; anti–IL‐13; anti–IL‐4; biologic agents; chronic rhinosinusitis; dupilumab; monoclonal antibody; nasal polyposis; type 2 inflammation

Year:  2021        PMID： 33768860      PMCID： PMC7981721          DOI： 10.1002/ccr3.3792

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  1 in total

Review 1.  Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps.

Authors:  Andrea Rampi; Alessandro Vinciguerra; Umberto Tanzini; Mario Bussi; Matteo Trimarchi
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-13       Impact factor: 3.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.